Traders Analysis -Genentech (DNA)

Genentech shares fell 1.6% in after-hours trading Tuesday after the biotech company reported results for the third quarter. The company posted earnings of 55 cents per share on revenue of $2.38 billion. Genentech was expected to announce a profit of 50 cents per share on revenue of $2.31 billion, according to analysts surveyed by Thomson First Call. Investors appeared to be disappointed by the quarterly performance of key products Avastin and Rituxan, as sales for both cancer drugs missed Street expectations.